Loading
Stomach Neoplasms / Pancreatic Neoplasms / Thymoma · Observational Study
ClinicalTrials.gov · August 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prospective observational registry and biobank study sponsored by the National Cancer Institute designed to collect tissue, blood, urine, and body fluid samples from up to 1000 patients with malignant mesothelioma and related mesothelin-expressing malignancies, with documentation of disease course and treatment. No clinical trial results have been posted; the registry record describes enrollment criteria and planned sample collection and analysis methods only.
Observational. Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma, Biliary Tract Neoplasms, Mesothelin Expressing Neoplasms; age from 2 Years; to 100 Years. Intervention: 1/Eligible cancer diagnosis. n = 1,000. 1 site: United States.
This is a prospective observational registry and biobank study sponsored by the National Cancer Institute designed to collect tissue, blood, urine, and body fluid samples from up to 1000 patients with malignant mesothelioma and related mesothelin-expressing malignancies, with documentation of disease course and treatment. No clinical trial results have been posted; the registry record describes enrollment criteria and planned sample collection and analysis methods only.
Primary outcome is tissue/sample acquisition, not clinical efficacy or safety.
This registry is designed to build a biobank to support future research on mesothelioma and mesothelin-expressing cancers. Clinicians should be aware this study is actively enrolling and may help enable future mechanism and biomarker research; however, no treatment recommendations or prognostic information can be drawn from a registry record with no posted results.
This is a recruiting observational tissue procurement and natural history registry with no results posted; it describes planned enrollment and sample collection methods only.
As stated by the source record.
Quoted from the source exactly as published.
This registry is designed to build a biobank to support future research on mesothelioma and mesothelin-expressing cancers. Clinicians should be aware this study is actively enrolling and may help enable future mechanism and biomarker research; however, no treatment recommendations or prognostic information can be drawn from a registry record with no posted results.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT01950572). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 1000 participants (ESTIMATED). Conditions: Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma, Biliary Tract Neoplasms, Mesothelin Expressing Neoplasms. Primary outcome measures: sample aquisition , Ongoing. Brief summary: Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States. * The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis. * Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease. * In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma. Objectives: -To allow sample acquisition for use in the study of mesothelioma. Eligibility: * All participants age greater than or equal to 2 years with malignant mesothelioma OR * All participants greater than or equal to 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin * Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18 Design: * Up to 1000 subjects will be enrolled. * Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma. * Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking. * Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.